Amphastar Pharmaceuticals (AMPH) Net Margin (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted Net Margin of 16.5% for Q2 2026, up 339.98% on a QoQ basis from 3.75% in Q1 2026, and down 129.0% year-over-year from 56.9% in Q2 2025.
Powered by 
Analysis
Amphastar Pharmaceuticals (AMPH) Net Margin (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals has reported Net Margin for 14 years, with the latest figure at 16.5% in Q2 2026.
- On a quarterly basis, Net Margin fell 129.0% year-over-year to 16.5% in Q2 2026; TTM through Jun 2026 was 11.43%, a 559.0% decrease from a year earlier, with the FY2025 full-year figure at 14.31%, down 596.0% from the prior year.
- Net Margin was 16.5% for Q2 2026 at Amphastar Pharmaceuticals, up from 3.75% in the prior quarter.
- The five-year high for Net Margin was 27.48% in Q3 2023, with the low at 3.75% in Q1 2026.
- Average Net Margin over 5 years is 17.38%, with a median of 17.96% recorded in 2025.
- The largest YoY upside for Net Margin was 1689 bps in 2022 against a maximum downside of 1424 bps in 2022.
- Over 5 years, Net Margin stood at 21.67% in 2022, then slipped by 14 bps to 18.74% in 2023, then fell by 25 bps to 14.07% in 2024, then grew by 14 bps to 16.02% in 2025, then increased by 3 bps to 16.5% in 2026.
- The last three Net Margin figures came in at 16.5% (Q2 2026), 3.75% (Q1 2026), and 16.02% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.81 Bn | 39.16 Bn | 2.15 Bn | -13.91% |
| 2 | Viatris | 19.17 Bn | 18.28 Bn | 1.46 Bn | -3.16% |
| 3 | Dr Reddys Laboratories | 9.90 Bn | 9.73 Bn | 396.53 Mn | 5.50% |
| 4 | Amneal Pharmaceuticals | 5.47 Bn | 5.35 Bn | 334.51 Mn | 8.74% |
| 5 | Bausch Health Companies | 2.32 Bn | 479.50 Mn | 2.10 Bn | 9.12% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -121.81% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.12 Bn | 165.89 Mn | 9.28% |
| 8 | Amphastar Pharmaceuticals | 997.70 Mn | 707.58 Mn | 93.47 Mn | 16.50% |
| 9 | Fennec Pharmaceuticals | 395.89 Mn | 354.64 Mn | 17.15 Mn | 11.04% |
| 10 | RedHill Biopharma | 179.21 Mn | 179.21 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.50% |
| Mar 31, 2026 | 3.75% |
| Dec 31, 2025 | 16.02% |
| Sep 30, 2025 | 9.04% |
| Jun 30, 2025 | 17.79% |
| Mar 31, 2025 | 14.83% |
| Dec 31, 2024 | 14.07% |
| Sep 30, 2024 | 21.14% |
| Jun 30, 2024 | 20.81% |
| Mar 31, 2024 | 25.46% |
| Dec 31, 2023 | 18.74% |
| Sep 30, 2023 | 27.48% |
| Jun 30, 2023 | 18.14% |
| Mar 31, 2023 | 19.15% |
| Dec 31, 2022 | 21.67% |
| Sep 30, 2022 | 13.35% |
| Jun 30, 2022 | 14.25% |
| Mar 31, 2022 | 20.73% |
| Dec 31, 2021 | 16.52% |
| Sep 30, 2021 | 27.59% |